BioCentury | Mar 25, 2019
Distillery Therapeutics

Two promoters of FMR1 expression to treat Fragile X syndrome

...Jerusalem, Jerusalem, Israel email: nissimb@mail.huji.ac.il CONTACT: Tamir Ben-Hur, Hadassah University Medical Center, Jerusalem, Israel email: tamir@hadassah.org.il Claire...
BioCentury | Mar 2, 2018
Financial News

Eye infection company Okogen raises $10M series A

...formulation of ranpirnase had advanced into late-stage development to treat mesothelioma until Alfacell Corp., now Tamir Biotechnology Inc....
...by FDA in 2009 to support approval. Okogen Inc., San Diego, Calif. Jaime De Leon ranpirnase Alfacell Corp. Allergan plc Tamir Biotechnology Inc. OKG-0301 Okogen...
BioCentury | Feb 27, 2018
Financial News

Eye infection company Okogen raises $10M series A

...formulation of ranpirnase had advanced into late-stage development to treat mesothelioma until Alfacell Corp., now Tamir Biotechnology Inc....
BioCentury | Feb 28, 2017
Distillery Techniques

Drug platforms

...la Cruz, M. et al. Nat. Methods ; published online Feb. 13, 2017 doi:10.1038/nmeth.4178 CONTACT: Tamir...
BioCentury | May 11, 2015
Clinical News

Tamir preclinical data

...70-80% vs. 0% for untreated control animals. TMR004 is a broad-spectrum type III ribonuclease (RNase). Tamir Biotechnology Inc....
BioCentury | Mar 3, 2014
Company News

Arno management update

...Hired: Lawrence Kenyon as CFO, formerly CFO, corporate secretary and interim president and CEO of Tamir Biotechnology Inc. WIR...
BioCentury | Apr 15, 2013
Clinical News

Onconase cytotoxic pancreatic RNase data

...asbestos exposure. A Phase III trial comparing Onconase and doxorubicin treatment is ongoing (see B12) Alfacell...
BioCentury | Oct 11, 2010
Clinical News

Tamir preclinical data

...in which a higher SI indicates greater antiviral activity. Onconase is a cytotoxic ribonuclease (RNase). Tamir Biotechnology Inc....
BioCentury | Aug 2, 2010
Clinical News

Tamir preclinical data

...EC50 concentration and EC90 cell inhibitory concentration in stationary cells (SI=EC50/EC90). In 2008, Tamir (formerly Alfacell...
...improving survival vs. doxorubicin alone in a Phase IIIb trial to treat unresectable malignant mesothelioma. Tamir Biotechnology Inc....
BioCentury | Aug 2, 2010
Clinical News

Tamir preclinical data

...EC90 cell inhibitory concentration in stationary cells (SI=EC50/EC90). Amphinase is an amphibian-based cytotoxic ribonuclease (RNase). Tamir Biotechnology Inc....
Items per page:
1 - 10 of 115
BioCentury | Mar 25, 2019
Distillery Therapeutics

Two promoters of FMR1 expression to treat Fragile X syndrome

...Jerusalem, Jerusalem, Israel email: nissimb@mail.huji.ac.il CONTACT: Tamir Ben-Hur, Hadassah University Medical Center, Jerusalem, Israel email: tamir@hadassah.org.il Claire...
BioCentury | Mar 2, 2018
Financial News

Eye infection company Okogen raises $10M series A

...formulation of ranpirnase had advanced into late-stage development to treat mesothelioma until Alfacell Corp., now Tamir Biotechnology Inc....
...by FDA in 2009 to support approval. Okogen Inc., San Diego, Calif. Jaime De Leon ranpirnase Alfacell Corp. Allergan plc Tamir Biotechnology Inc. OKG-0301 Okogen...
BioCentury | Feb 27, 2018
Financial News

Eye infection company Okogen raises $10M series A

...formulation of ranpirnase had advanced into late-stage development to treat mesothelioma until Alfacell Corp., now Tamir Biotechnology Inc....
BioCentury | Feb 28, 2017
Distillery Techniques

Drug platforms

...la Cruz, M. et al. Nat. Methods ; published online Feb. 13, 2017 doi:10.1038/nmeth.4178 CONTACT: Tamir...
BioCentury | May 11, 2015
Clinical News

Tamir preclinical data

...70-80% vs. 0% for untreated control animals. TMR004 is a broad-spectrum type III ribonuclease (RNase). Tamir Biotechnology Inc....
BioCentury | Mar 3, 2014
Company News

Arno management update

...Hired: Lawrence Kenyon as CFO, formerly CFO, corporate secretary and interim president and CEO of Tamir Biotechnology Inc. WIR...
BioCentury | Apr 15, 2013
Clinical News

Onconase cytotoxic pancreatic RNase data

...asbestos exposure. A Phase III trial comparing Onconase and doxorubicin treatment is ongoing (see B12) Alfacell...
BioCentury | Oct 11, 2010
Clinical News

Tamir preclinical data

...in which a higher SI indicates greater antiviral activity. Onconase is a cytotoxic ribonuclease (RNase). Tamir Biotechnology Inc....
BioCentury | Aug 2, 2010
Clinical News

Tamir preclinical data

...EC50 concentration and EC90 cell inhibitory concentration in stationary cells (SI=EC50/EC90). In 2008, Tamir (formerly Alfacell...
...improving survival vs. doxorubicin alone in a Phase IIIb trial to treat unresectable malignant mesothelioma. Tamir Biotechnology Inc....
BioCentury | Aug 2, 2010
Clinical News

Tamir preclinical data

...EC90 cell inhibitory concentration in stationary cells (SI=EC50/EC90). Amphinase is an amphibian-based cytotoxic ribonuclease (RNase). Tamir Biotechnology Inc....
Items per page:
1 - 10 of 115